Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 19/20 | 0.69 |
| ▸ | ADRA1D | P25100 | 18/20 | 0.69 |
| ▸ | ADRA1B | P35368 | 18/20 | 0.69 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7075961 | 1.00 | ADRA1A (0.69) | ADRA1AADRA1DADRA1BMCHR1 | |
| SCHEMBL7162689 | 1.00 | ADRA1A (0.69) | ADRA1AADRA1DADRA1BMCHR1 | |
| SCHEMBL7075958 | 1.00 | ADRA1A (0.69) | ADRA1AADRA1DADRA1BMCHR1 | |
| SCHEMBL7079830 | 1.00 | ADRA1A (0.69) | ADRA1AADRA1DADRA1BMCHR1 | |
| Hydrochloric Acid SCHEMBL7081420 | 0.99 | ADRA1A (0.68) | ADRA1AADRA1DADRA1BMCHR1 | |
| Hydrochloric Acid SCHEMBL7076911 | 0.99 | ADRA1A (0.68) | ADRA1AADRA1DADRA1BMCHR1 | |
| SCHEMBL7966364 | 0.95 | ADRA1A (0.67) | ADRA1AADRA1DADRA1BMCHR1 | |
| SCHEMBL7966363 | 0.95 | ADRA1A (0.67) | ADRA1AADRA1DADRA1BMCHR1 | |
| SCHEMBL7163560 | 0.94 | ADRA1A (0.62) | ADRA1AADRA1DADRA1BMCHR1 | |
| SCHEMBL7966193 | 0.94 | ADRA1A (0.62) | ADRA1AADRA1DADRA1BMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6255315-B1 | BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2001-07-03 | — | — | US | disclosed |
| US-6037354-A | ADMINISTERING PHENYL-SUBSTITUTED THIAZOLIDIN-4-ONE OR OXAZOLIDIN-2-ONE DERIVATIVE TO TREAT BENIGN PROSTATE HYPERPLASIA; SIDE EFFECT REDUCTION | MERCK & CO., INC. (US) | 2000-03-14 | — | — | US | disclosed |